Perfusion-based manufacturing is attracting renewed attention as biologics developers confront mounting pressure to increase output while reining in costs, according to Genetic Engineering News. The continuous cell culture method, which offers higher volumetric productivity compared to traditional fed-batch processes, is seeing accelerated commercial deployment driven by recent technological breakthroughs.
Improvements in cell culture media formulations, along with automation and AI-driven process control systems, are helping overcome long-standing barriers to perfusion adoption. These advances enable real-time monitoring and adjustment of nutrient feed rates, reducing waste and improving product consistency. Industry observers note that the shift could significantly lower the cost of goods for complex biologics.
Despite the momentum, perfusion systems remain more complex to implement than batch processes, requiring specialized equipment and expertise. The upfront capital investment and the need for robust validation protocols have slowed uptake among smaller manufacturers. However, the technology's ability to boost yields by up to 10-fold in some applications makes it increasingly attractive for high-value therapies.
No specific companies or financial figures were cited in the report, which focused on broad industry trends rather than individual corporate announcements. The post appeared on GEN - Genetic Engineering and Biotechnology News, a verified industry publication.
While the article presents perfusion as a growing trend, it is worth noting that adoption rates vary widely by region and product type, and many established biologics manufacturers remain committed to fed-batch processes. The long-term cost-benefit analysis for switching to perfusion is still being debated within the industry.